Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-077 in advanced breast cancer and solid tumors
NCT06609187Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Multispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GNC-077 in breast cancer and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
GNC-077
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT06609187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609187.